$EXPO

Corrigan Catherine sold $109K of EXPO

Corrigan Catherine (Chief Executive Officer) sold 1,737 shares of EXPONENT INC (EXPO) at $62.78 ($0.11M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Corrigan Catherine
Published Jul 17, 2026, 11:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 11:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXPO
Neutral
high confidence
Mentioned
$EXPO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXPONeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value) and confirmation of a pre-arranged 10b5-1 plan; there is no operational or financial update.

02

Market read

Primarily a sentiment datapoint for EXPO, with limited fundamental implications due to 10b5-1 pre-arrangement.

03

What to watch

Traders may over-weight insider sales; without changes to guidance, contracts, or financial results, the signal is typically weak.

Relevance 3/10Novelty 3/10Timing: after-hours/filing date disclosure on 2026-07-17

Background

The article is a SEC Form 4 insider transaction disclosure for Exponent Inc (EXPO).

Company-level read

Ticker impact

$EXPONeutralHigh confidence
Context

Exponent CEO Corrigan Catherine sold 1,737 shares in an open-market transaction on 2026-07-15 under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any reaction would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly open-market and pre-arranged under a Rule 10b5-1 plan, with no accompanying fundamental news or guidance change.

Market effects

No clear sector read-through from a single CEO 10b5-1 sale.

None.

None.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Exponent Inc

    Company whose CEO filed the Form 4 insider sale disclosure.

  • Corrigan Catherine

    Exponent CEO and director who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXPOMedAI 8/10

What Exponent (EXPO) Said on Its Q3 Earnings Call

Exponent (EXPO) reported $171M in stock buybacks over the past year, reducing shares outstanding by 5%. Q3 saw $14.7M in dividends. Revenue grew 13% in engineering, 3% in environmental/health. AI-related work is 15-20% of business. Q4 outlook: 8-10% revenue growth, 26.3-26.8% EBITDA margin. Full-year 2026 outlook raised: 10-11% revenue growth, 28-28.3% EBITDA margin.